Ibrutinib-A double-edge sword in cancer and autoimmune disorders

摘要: Targeted therapies have appeared as new treatment options for several disease types, including cancer and autoimmune disorders. Of targets, tyrosine kinases (TKs) are among the most promising. Overexpression of TKs provides a target novel therapeutic agents, small molecule inhibitors (TKI). Ibrutinib (PCI-32765) is TKI Bruton's kinase (Btk), key B-cell receptor signaling pathway that plays significant role in proliferation, differentiation survival B cells. In addition to inhibitory effects, recent studies shown ibrutinib has multiple immunomodulatory effects. It binds covalently IL-2 inducible (Itk) T lymphocytes suppresses T-helper (Th) 2 This changes balance Th1/Th2 cells toward Th1 subset, which main immune targeting tumor The dual activity paid great attention evaluating anti-tumor effects cancer, disorders infectious diseases. this article we review malignancies, diseases infections, well communication between Ror1 BCR on crosstalk.